文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

低剂量利伐沙班与晚期肾病心血管事件:TRACK随机临床试验

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论晚期CKD高心血管风险患者中,低剂量利伐沙班未降低复合心血管结局,且大出血显著增加。

TRACK试验为随机、双盲、安慰剂对照研究,在12个国家90个中心纳入1458例CKD 4期或5期及透析依赖肾衰竭患者,随机接受利伐沙班2.5 mg每日两次或安慰剂。中位随访1.7年,主要复合终点(心血管死亡、非致死性心肌梗死、卒中或外周动脉疾病事件)在利伐沙班组为22.6%、安慰剂组为20.7%(HR 1.09,95%CI 0.87-1.36,P=.46),无显著差异。大出血在利伐沙班组为8.8%、安慰剂组为6.0%(HR 1.51,95%CI 1.02-2.22,P=.04),利伐沙班组显著更高。该试验因缺乏疗效于2025年8月7日提前终止。

要点

  • 晚期CKD高心血管风险患者中,利伐沙班2.5 mg每日两次较安慰剂未降低主要复合心血管终点(22.6% vs 20.7%;HR 1.09,95%CI 0.87-1.36,P=.46)。
  • 利伐沙班组大出血发生率显著高于安慰剂组(8.8% vs 6.0%;HR 1.51,95%CI 1.02-2.22,P=.04)。
  • 试验因缺乏疗效提前终止,最终随访于2025年10月30日完成。
  • 适用人群为CKD 4期或5期及透析依赖肾衰竭成人,且有冠心病、非出血性非腔隙性卒中、外周动脉疾病、糖尿病或年龄≥65岁。

适用人群与场景

  • 成人CKD 4期或5期患者及透析依赖肾衰竭患者。
  • 需有冠心病史、非出血性非腔隙性卒中史、外周动脉疾病史、糖尿病,或年龄≥65岁。

处置流程与药物剂量

  • 利伐沙班2.5 mg每日两次口服,与安慰剂对照;该方案在晚期CKD高心血管风险患者中未降低复合心血管终点且大出血增加。

研究设计与关键结果

  • 随机、双盲、安慰剂对照试验,在12个国家90个中心纳入1458例患者(平均年龄63.2岁,女性432例[29.6%]),1360例(93.3%)完成随访。
  • 中位随访1.7年,主要复合终点(心血管死亡、非致死性心肌梗死、卒中或外周动脉疾病事件)在利伐沙班组发生164例(22.6%)、安慰剂组151例(20.7%);13.0 vs 11.8事件/100人年;HR 1.09(95%CI 0.87-1.36),P=.46。
  • 大出血在利伐沙班组发生64例(8.8%)、安慰剂组44例(6.0%);5.1 vs 3.4事件/100人年;HR 1.51(95%CI 1.02-2.22),P=.04。
  • 试验于2025年8月7日因缺乏疗效提前终止,最终随访于2025年10月30日。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验。
  • 试验注册号:ClinicalTrials.gov NCT03969953。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在晚期CKD高心血管风险患者中,低剂量利伐沙班未降低复合心血管结局且大出血增加,不支持为该适应症使用该方案。
  • 适用人群为CKD 4期或5期及透析依赖肾衰竭且符合纳入标准者;不适用于无上述心血管风险特征的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Approximately 10% to 15% of patients with advanced chronic kidney disease (CKD) experience a fatal or nonfatal cardiovascular event annually. The effects of antithrombotic therapies on cardiovascular events in patients with advanced CKD are unknown.

OBJECTIVE: To determine whether low-dose rivaroxaban reduces rates of adverse cardiovascular events compared with placebo in patients with advanced CKD.

DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted at 90 centers in 12 countries. Eligible participants were adults with CKD stage 4 or 5 and patients with dialysis-dependent kidney failure. Participants had a history of either coronary artery disease; nonhemorrhagic, nonlacunar stroke; peripheral artery disease; diabetes; or were 65 years or older. Enrollment occurred between January 2021 and July 2025. The trial was stopped early on August 7, 2025, for lack of efficacy. Final follow-up occurred on October 30, 2025. Statistical analyses were conducted in February and March 2026.

INTERVENTIONS: Patients were randomized 1:1 to receive rivaroxaban 2.5 mg twice daily or placebo.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or a peripheral artery disease event. The primary safety outcome was major bleeding.

RESULTS: Of 1458 randomized patients (mean [SD] age, 63.2 [11.6] years, 432 [29.6%] female), 1360 (93.3%) completed follow-up. During a median follow-up of 1.7 years, the primary outcome occurred in 164 patients (22.6%) in the low-dose rivaroxaban group and 151 (20.7%) in the placebo group (13.0 vs 11.8 events per 100 person-years; hazard ratio, 1.09 [95% CI, 0.87-1.36]; P = .46). Major bleeding occurred in 64 patients (8.8%) receiving low-dose rivaroxaban and 44 (6.0%) receiving placebo (5.1 vs 3.4 events per 100 person-years; hazard ratio, 1.51 [95% CI, 1.02-2.22]; P = .04).

CONCLUSIONS AND RELEVANCE: In patients with advanced CKD at high cardiovascular risk, low-dose rivaroxaban did not reduce the risk of a composite cardiovascular outcome. Major bleeding rates were significantly higher in the low-dose rivaroxaban group compared with the placebo group.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03969953.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Badve SV, Perkovic V, Jha V, et al. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. JAMA. 2026. PMID: 42240165. doi:10.1001/jama.2026.9379

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。